Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome
Status:
Active, not recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of azacitidine and pembrolizumab and to see how
well they work in treating patients with myelodysplastic syndrome. Azacitidine may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
azacitidine and pembrolizumab may work better at treating myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)